Remote Patient Management:

Slides:



Advertisements
Similar presentations
Outcome of Patients with Advanced Heart Failure who Receive Device- Based Therapy for Primary Prevention of Sudden Cardiac Death, G. Amit, N. Samniah,
Advertisements

Clinical Characteristics and Outcomes of Elderly Patients Treated With ICD and CRTD in Real World Setting: Data From the Israeli ICD Registry M. Suleiman,
? What more will it take to turn the tide of treatment for angina patients from a PCI-first to an optimal medical therapy– first approach? 1.
Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: Clinical Effectiveness of CRT and ICD Therapy in.
Wearable Cardioverter Defibrillators
The Nurse’s Role in Inflammatory Bowel Disease
Trends in Coronary Procedures per 1000 Medicare Beneficiaries
Exploring Early Combination Therapy in PAH
Hospitalizations and Healthcare Costs Need for Reduction in Hospitalizations of Patients With HF
ICD-10 and Clinical Documentation
New Guidelines to Prevent SCD: What You Need to Know
Current Dyslipidemia Management Guidelines Residual Risk.
Atrial Fibrillation and PCI
Breaking Barriers in PAH: Role of Novel Early Treatment Strategies
CathPCI-NCDR Registry Mortality (STEMI)
Risk Stratification in PAH: What Do the Latest Data Suggest?
Acute Heart Failure.
A Paradigm Shift in PAH.
The Clinical Enigma of Cardiogenic Shock
NOACs, AF, and PCI: What Do the Latest Data Suggest?
Heart Failure and Hospital Readmissions
Achieving Long-Term Protection Post-MI
Preventing SCD With a WCD: Reviewing the Results of the VEST Trial
Addressing Patients at High Risk for SCA
A CASE CHALLENGE IN HFrEF:
PAD Patients vs Post-ACS Patients:
A New Era for NOACs:.
Renal and Extrarenal Complications of ADPKD: Facilitating Better Patient Care.
Anticoagulation Highlights From the American Heart Association Meeting 2017.
Select Topics in Cardiovascular Medicine
New Perspectives in AF and PCI: Implications for the Practicing Physician.
Patient Presentation Patient’s Changing Condition Multiple Considerations To Balance.
It’s Elementary.
Adverse Neurohormonal Activation in HF Has Formed the Basis for Evidence-Based Pharmacologic Therapy
How and When to Decide on Revascularization in Stable Ischemic Heart Disease.
Recurrent Angina: New Tools for an Old Problem
A Case Challenge: Anticoagulant Choices for Acute PE
Heart Failure Prevention: Mission Impossible?
PAH Therapy Revisited.
Improving Risk Assessment and Early Diagnosis in PAH
Are We Closer to Personalized Medicine in MS?
Selected Highlights of the Latest Advances in PAH
Opportunities and Challenges in the Management of Advanced STS
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
What Anticoagulant Registries Are Revealing
A Hard Look at Cardiogenic Shock: IABP-SHOCK II Revisited
Examining the Latest Evidence in PAH
Translating the Latest and Greatest Advances in PAH Into Clinical Practice.
LEADER One Year On.
EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.
Physiology Myocardial Oxygen Supply and Demanda,b.
Revisiting the Pharmacoeconomics of HF
Navigating Treatment Options in PAH
Identifying High-Risk AF Patients
Trials and Tribulations in VTE: How Do Real-World Data Fit In?
The Challenge of AF and PCI: Practical Strategies to Improve Outcomes
Improving Adherence to Antiplatelet Therapy After an ACS Event
Practical Tools for SCA Screening
Breaking Barriers in PAH: Role of Novel Early Treatment Strategies
Clinical Challenges in the Patient With Relapsed Multiple Myeloma
Incorporating New PAH Treatments Into Clinical Practice
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
Pulmonary Arterial Hypertension and Hospitalizations
Importance of Early Diagnosis and Management in SMA
My PAH Patient.
Top Tips in Evidence-Based Care for HFrEF
Rethinking Risk Stratification for Nonischemic HF:
The Power of As-Treated Analyses
Diagnosing HFpEF: What Every Cardiologist Needs to Know
Translating Data From Trial to Practice
Presentation transcript:

Remote Patient Management:

Learning Objectives

Characteristics of Patients After MI Coming to the Catheterization Lab

Cleveland Clinic Post-PCI Registry WCD Use Associated With Improved Survival

VALIANT Trial High Early Risk of SCA

CADILLAC Risk Score

Use of Evidence-based Therapies in HF After an MI

Mechanism of Death in HF

Use of the WCD in Peripartum CMP

WEARIT-II Compliance

WEARIT-II Study Population

WEARIT-II ICD Implantation Rate by Disease Etiology

The WCD A Tool for Therapy and Diagnosis

Patients After PCI Avoiding Readmission

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)